Stockreport

Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]

Vanda Pharmaceuticals Inc.  (VNDA) 
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm Check Earnings Report
PDF VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and SG&A drove a $22.6M net loss, reflecting a strategic investment phase. The company maintains a robust $29 [Read more]